Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BNTC NASDAQ:IMAB NASDAQ:ORMP NASDAQ:UPXI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTCBenitec Biopharma$13.78-1.4%$12.52$8.06▼$17.15$361.73M0.4367,092 shs11,328 shsIMABI-Mab$4.09+4.9%$3.38$0.60▼$5.90$337.66M1.361.00 million shs1.08 million shsORMPOramed Pharmaceuticals$2.41-0.8%$2.16$1.82▼$3.09$97.99M1.69137,194 shs93,693 shsUPXIUpexi$6.70+17.9%$6.24$1.90▼$22.57$393.44M-0.473.86 million shs9.29 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTCBenitec Biopharma+4.80%-0.14%+12.83%-15.17%+65.64%IMABI-Mab-6.70%-10.34%+1.30%+56.63%+264.49%ORMPOramed Pharmaceuticals+4.29%+9.46%+15.71%+14.08%+2.10%UPXIUpexi+4.03%-10.27%-14.71%-43.26%+46.32%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTCBenitec Biopharma$13.78-1.4%$12.52$8.06▼$17.15$361.73M0.4367,092 shs11,328 shsIMABI-Mab$4.09+4.9%$3.38$0.60▼$5.90$337.66M1.361.00 million shs1.08 million shsORMPOramed Pharmaceuticals$2.41-0.8%$2.16$1.82▼$3.09$97.99M1.69137,194 shs93,693 shsUPXIUpexi$6.70+17.9%$6.24$1.90▼$22.57$393.44M-0.473.86 million shs9.29 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTCBenitec Biopharma+4.80%-0.14%+12.83%-15.17%+65.64%IMABI-Mab-6.70%-10.34%+1.30%+56.63%+264.49%ORMPOramed Pharmaceuticals+4.29%+9.46%+15.71%+14.08%+2.10%UPXIUpexi+4.03%-10.27%-14.71%-43.26%+46.32%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNTCBenitec Biopharma 3.13Buy$26.0088.68% UpsideIMABI-Mab 3.00Buy$7.0071.15% UpsideORMPOramed Pharmaceuticals 0.00N/AN/AN/AUPXIUpexi 3.50Strong Buy$15.50131.52% UpsideCurrent Analyst Ratings BreakdownLatest ORMP, BNTC, IMAB, and UPXI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/10/2025IMABI-MabNew Street ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$7.009/9/2025IMABI-MabBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$7.009/8/2025IMABI-MabNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.008/28/2025IMABI-MabLoop CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$8.008/28/2025IMABI-MabBrookline Capital ManagementSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/21/2025IMABI-MabHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.008/20/2025IMABI-MabNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.00 ➝ $6.008/13/2025UPXIUpexiCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/4/2025UPXIUpexiAlliance Global PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$15.007/9/2025IMABI-MabNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.007/9/2025IMABI-MabHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNTCBenitec Biopharma$80K4,521.56N/AN/A$4.68 per share2.94IMABI-Mab$3.89M85.86N/AN/A$2.47 per share1.66ORMPOramed Pharmaceuticals$1.34M73.74N/AN/A$3.61 per share0.67UPXIUpexi$26M15.16N/AN/A$6.24 per share1.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNTCBenitec Biopharma-$21.75M-$1.51N/AN/AN/AN/A-38.26%-35.71%9/25/2025 (Estimated)IMABI-Mab-$22.23MN/A0.00N/AN/AN/A-19.65%-18.58%11/13/2025 (Estimated)ORMPOramed Pharmaceuticals-$19.06M-$0.35N/AN/AN/AN/A-19.37%-18.28%11/6/2025 (Estimated)UPXIUpexi-$23.66MN/A0.00∞N/A-135.86%-535.19%-122.94%9/29/2025 (Estimated)Latest ORMP, BNTC, IMAB, and UPXI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/25/2025Q4 2025BNTCBenitec Biopharma-$0.24N/AN/AN/AN/AN/A8/20/2025Q2 2025IMABI-Mab-$0.10-$0.07+$0.03-$0.07N/AN/A8/14/2025Q2 2025ORMPOramed Pharmaceuticals-$0.04-$0.05-$0.01$0.31N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBNTCBenitec BiopharmaN/AN/AN/AN/AN/AIMABI-MabN/AN/AN/AN/AN/AORMPOramed PharmaceuticalsN/AN/AN/AN/AN/AUPXIUpexiN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNTCBenitec Biopharma0.0114.8014.80IMABI-MabN/A22.8222.82ORMPOramed PharmaceuticalsN/A26.8226.81UPXIUpexi0.310.370.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNTCBenitec Biopharma52.19%IMABI-Mab38.38%ORMPOramed Pharmaceuticals12.73%UPXIUpexi5.68%Insider OwnershipCompanyInsider OwnershipBNTCBenitec Biopharma1.30%IMABI-Mab22.10%ORMPOramed Pharmaceuticals17.80%UPXIUpexi4.42%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNTCBenitec Biopharma2026.25 million25.91 millionNo DataIMABI-Mab38081.66 million63.61 millionOptionableORMPOramed Pharmaceuticals1041.00 million33.71 millionOptionableUPXIUpexi13058.89 million56.29 millionOptionableORMP, BNTC, IMAB, and UPXI HeadlinesRecent News About These CompaniesUpexi Stock Pops Pre-Market, Retail Chatter Surges On Growing Solana Treasury Holdings5 hours ago | msn.comUpexi's Stellar Gains: Solana Treasury Strategy Drives 129% Growth in SOL ValueSeptember 12 at 5:56 AM | econotimes.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Upexi, Inc. (NASDAQ: UPXI)September 11 at 8:30 AM | prnewswire.comUpexi Adjusted SOL per Share Increases 129% Since Treasury LaunchSeptember 11 at 8:00 AM | globenewswire.comSolana gains 5% as Forward Industries reveals $1.6 billion SOL treasury planSeptember 8, 2025 | fxstreet.comUpexi Engages in September 2025 Investor ConferencesSeptember 8, 2025 | tipranks.comUpexi (NASDAQ:UPXI) Stock Price Down 4.5% - What's Next?September 7, 2025 | marketbeat.comUpexi to Participate in Upcoming September ConferencesSeptember 3, 2025 | manilatimes.netMBitcoin Gains As ‘September Slump’ Remains Uncertain – Retail Traders Bet On Break From Trend In 2025September 3, 2025 | msn.comUpexi, Inc. Announces Strategic Investment in Alpha ExchangeAugust 28, 2025 | markets.businessinsider.comUpexi Invests in Alpha Exchange for Revenue ShareAugust 27, 2025 | tipranks.comUpexi Amends Securities Purchase AgreementAugust 26, 2025 | msn.comUpexi Approves Share Increase and New AgreementAugust 20, 2025 | tipranks.comUpexi (NASDAQ:UPXI) Trading Down 10% - Time to Sell?August 17, 2025 | marketbeat.comUpexi, Inc. (NASDAQ:UPXI) Short Interest UpdateAugust 17, 2025 | marketbeat.comUpexi (NASDAQ:UPXI) Shares Gap Down - Here's What HappenedAugust 16, 2025 | marketbeat.comUpexi (NASDAQ:UPXI) Stock Rating Upgraded by Cantor FitzgeraldAugust 16, 2025 | marketbeat.comDigital Asset Treasury Firms Plunge as Bitcoin Tumbles Below $117K, ETH Slides to $4.4KAugust 15, 2025 | coindesk.comUpexi (NASDAQ:UPXI) Shares Gap Up - Time to Buy?August 15, 2025 | marketbeat.comFormer Amazon aggregator turns to Solana, records $70K in daily rewardsAugust 13, 2025 | msn.comUpexi establishes Advisory Committee, welcomes Hayes as first memberAugust 13, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeORMP, BNTC, IMAB, and UPXI Company DescriptionsBenitec Biopharma NASDAQ:BNTC$13.78 -0.20 (-1.43%) As of 03:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.I-Mab NASDAQ:IMAB$4.09 +0.19 (+4.87%) As of 03:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.Oramed Pharmaceuticals NASDAQ:ORMP$2.41 -0.02 (-0.82%) As of 03:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.Upexi NASDAQ:UPXI$6.70 +1.02 (+17.87%) As of 03:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Intel's Silent Comeback: 3 Pillars the Market Is Overlooking Palantir’s Defense Partnerships Fuel Its Growth Story It May Be Time to Buy the Dip in Texas Instruments Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
